7UX Stock Overview
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden.
Notes are coming soon
Spago Nanomedical AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.062|
|52 Week High||kr0.39|
|52 Week Low||kr0.049|
|1 Month Change||12.73%|
|3 Month Change||-38.00%|
|1 Year Change||-84.06%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-91.53%|
Recent News & Updates
|7UX||DE Biotechs||DE Market|
Return vs Industry: 7UX underperformed the German Biotechs industry which returned 6% over the past year.
Return vs Market: 7UX underperformed the German Market which returned -7.1% over the past year.
|7UX Average Weekly Movement||16.8%|
|Biotechs Industry Average Movement||5.7%|
|Market Average Movement||5.2%|
|10% most volatile stocks in DE Market||10.6%|
|10% least volatile stocks in DE Market||2.4%|
Stable Share Price: 7UX is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: 7UX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
Spago Nanomedical AB (publ) Fundamentals Summary
|7UX fundamental statistics|
Is 7UX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|7UX income statement (TTM)|
|Cost of Revenue||kr20.35m|
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-606.76%|
How did 7UX perform over the long term?See historical performance and comparison